Harnessing heritage and passion to power innovation · world-class biopharmaceutical business. We...

Harnessing heritage and passion to power innovation

Passion.People.Possibilities.®

The story of AbbVie in Ireland

Dedication, Development & Delivery 2

Our Irish Innovation Story 6

Delivering Value to Society 15

A Passion for our People 21

Corporate Responsibility 24


1

Dedication, Development & Delivery

AbbVie combines the dynamism, energy and agility of a start-up with 125 years of heritage and experience to create a world-class biopharmaceutical business.

We are dedicated to developing and delivering a stream of innovative medicines which make a remarkable impact on the lives of patients.

Name SurnameJob Title, AbbVie Sligo

Ollie KinloughAbbVie Citywest, Dublin

Dedication, Development & Delivery 32 Harnessing heritage and passion to power innovation: The story of AbbVie in Ireland

AbbVie is a global, research-based biopharmaceutical company with 30,000 employees. We are dedicated to developing and delivering a stream of innovative medicines which make a remarkable impact on the lives of patients.

We have an absolute commitment to our patients, and we draw on our deep expertise in some of the most difficult-to-treat diseases to deliver hope to those in need.

AbbVie has a proud track record of bringing innovative therapies to patients. Today, our medicines benefit more than 30 million people in 175 countries.

Our business is built on science and innovation. We concentrate on discovering, developing and delivering medicines where we have a proven expertise and can make a positive impact on patients’ lives.

“Our consistently strong financial performance ensures that we have the resources to support complex research…”

Our key areas of focus are immunology, oncology, virology and neuroscience. We also apply our scientific expertise to discover and develop medicines in other areas where patients still have limited treatment options.

Tackling the toughest health care challenges requires a collaborative approach and AbbVie works with hundreds of biotech companies, universities,

AbbVie takes a comprehensive approach to tackling the toughest health care challenges. Our scientists are leaders in their fields and inspire us to do all we can to bring medicines to patients quickly and safely.

Our impact stretches beyond our medicines and we provide a broad range of supports to patients while also playing an active role in the communities where we live and work.

non-profit organisations, scientific research centres, and government organisation to advance research.

Our own state-of-the-art research and development facilities are located in some of the world’s most productive innovation hubs. This puts us at the leading edge of global research efforts and enables us to move our best ideas forward faster as we continue to develop our robust pipeline of potential new treatments.

Our advanced manufacturing centres in Ireland, the US, Puerto Rico, Italy, Germany and Singapore continue to explore new ways of delivering our discoveries safely and reliably to patients.

Our strong financial performance ensures we have the resources to support the complex research required to meet today’s health challenges, while delivering an industry leading investment return to shareholders. This allows us to develop the treatments of tomorrow that demonstrate both strong clinical performance and strong economic value.

A Global, Research-Based Biopharmaceutical Company

Tackling the toughest healthcare challenges

30m+patients treated with AbbVie’s medicines every year

175+countries where our products help people

30,000employees around the world

Gareth TolanAbbVie Santry, Dublin

4 Harnessing heritage and passion to power innovation: The story of AbbVie in Ireland Dedication, Development & Delivery 5

Our Irish Innovation Story

AbbVie delivers societal value in Ireland in many ways – positively impacting the national economy, providing direct and indirect employment and supporting local communities, to take just some examples.

However, our most significant contribution is the supply of innovative medicines which have the potential to solve serious health issues and have a remarkable impact on people’s lives.

Nina NovakAbbVie Cork

Our Irish Innovation Story 76 Harnessing heritage and passion to power innovation: The story of AbbVie in Ireland

AbbVie has more than 700 employees across five sites in Ireland. Alongside three manufacturing facilities in Sligo and Cork, two offices in Dublin serve the needs of our commercial and manufacturing activities.

AbbVie has invested more than €300 million in Ireland since 2013 and each of our uniquely focused production sites here manufactures portions of AbbVie’s top 20 global products.

We are proud that AbbVie in Ireland is at the very heart of our company’s global business.

We harness Irish expertise in complex chemical and biological research, testing discoveries through clinical trials as well as manufacturing many of our medicines and delivery devices here in Ireland.

In this way, Ireland contributes to every part of the medicine discovery process before our commercial team works to make these new treatments accessible to Irish patients as quickly as possible.

“The Irish healthcare system needs new innovations…and we are proud of the role AbbVie is playing in addressing that challenge.”

We have proven expertise across the entire medicine discovery process, from original R&D through gold-standard local manufacturing through to innovative in-market therapies. The Irish healthcare system needs new approaches to meet the changing needs of an ageing population with multiple chronic diseases and we are proud of the role AbbVie is playing in addressing that challenge.

Ireland: at the heart of our global business

€300m+invested in Ireland since 2013

700+employees across Ireland

Sheila McLaughlin, Paul Dwyer and Caroline ConnollyAbbVie Manorhamilton Road, Sligo

8 Harnessing heritage and passion to power innovation: The story of AbbVie in Ireland Our Irish Innovation Story 9

Ballytivnan, Sligo

Our manufacturing site in Ballytivnan dates back to 1974 and currently produces drug delivery devices including a pen-style injector which is used by patients receiving an AbbVie treatment for a range of autoimmune conditions. In 2018, AbbVie announced a €113 million investment in new sterile manufacturing capability at the site.

AbbVie Ballytivnan was recently awarded the global Shingo Prize in recognition of the company’s enterprise excellence. AbbVie was one of only four companies in the world to be awarded the accolade.

Manorhamilton Road, Sligo

AbbVie’s Manorhamilton Road plant was established in 2002 to manufacture active pharmaceutical ingredients for both small molecules and drugs in the cardiology, neurology, oncology, virology, and urology therapeutic areas.

The site recently underwent a significant €85 million expansion that doubled its footprint and provided additional capability to support AbbVie’s new product introductions on a global basis.

Carrigtwohill, Cork

Established in 2001, our plant at Carrigtwohill is a modern bulk tablet finish facility. It manufactures solid and capsule formulations for worldwide distribution using innovative new technologies that advance and assure patient care.

The Cork team’s depth of expertise, coupled with highly sophisticated technology, enables the facility to deliver products and processes from small scale clinical trial supply to larger commercial manufacturing.

Citywest, Dublin

Our commercial headquarters at the Citywest Office Campus oversees the sale, supply, distribution and marketing of the company’s finished products in Ireland.

Santry, Dublin

Our Santry office is an international base for a range of manufacturing and engineering services and supports AbbVie plants all around the world.


AbbVie’s commitment to innovation is what has made us a successful company and our medicines now benefit more than 30 million people living in more than 175 countries, including Ireland. Our products are supported by a range of Irish-based services including Regulatory, Medical, Pharmacovigilance and Patient Support. This ensures health care practitioners are properly educated on our medicines and that patients are supported beyond the medicine to achieve an optimal outcome.

We’re studying compounds that have the potential to treat 1.5 billion people globally.

AbbVie’s future commercial focus is on developing a consistent stream of innovative medicines. This commitment to making a remarkable impact on people’s lives through the potential of focused innovation differentiates us amongst our peer group. We’re studying compounds that have the potential to treat 1.5 billion people globally.

Breakthroughs only come about because of the passion, commitment and the dedication of individuals, teams, and companies working to discover and develop new medicines for patients.

In late 2017, the European Federation of Pharmaceutical Industries and Associations (EFPIA) launched a pan-European campaign called #WeWontRest. It highlighted personal stories from people working in our industry in order to better explain biopharmaceutical innovation, demonstrate the value of medicines, and share insights on the future of R&D and healthcare in Europe.

AbbVie made its first public commitment to the #WeWontRest campaign with a pledge from one of our managers, Claire Rooney, who at that time was a Quality Control Laboratory Manager at AbbVie’s site in Cork. AbbVie Cork supports the

Treatments of tomorrow

We Won’t RestThese treatments of tomorrow will demonstrate both strong clinical performance and strong economic value. Spending on medicines must be set in the context of benefits and value. It is too often treated as a cost without consideration of the associated benefits for patients, society and the economy.

We believe the Irish healthcare system, when seeking sustainability solutions on multiple fronts, should fairly value the positive impact that such medicines can have on the lives of its citizens.

global supply of a wide range of therapies for conditions and diseases. Claire featured in an online and broadcast media campaign capturing AbbVie’s commitment to help discover much-needed cures and treatment for people around the world battling liver disease, cancer and other health challenges.

In her European campaign materials, video and radio advert, Claire explained why she was inspired to pursue a career in the pharmaceutical industry and why the work she does is rewarding. Her testimony also discusses AbbVie’s corporate responsibility commitment and shows Claire and colleagues participating in the company’s Week of Possibilities volunteering initiative.

Claire’s contribution has been promoted on social media platforms by a number of industry organisations, including the Irish Pharmaceutical Healthcare Association (IPHA) and EFPIA.

Claire RooneyAbbVie Manorhamilton Road, Sligo

Neil EwingAbbVie Manorhamilton Road, Sligo


Delivering Value to Society

Our global business model is supported by four key pillars, all of which play an important part in unlocking our ability to make a societal contribution…

Karen WalshAbbVie Citywest, Dublin

Delivering Value to Society 1514 Harnessing heritage and passion to power innovation: The story of AbbVie in Ireland

Phase one: Discovery

AbbVie makes a significant societal contribution through the discovery process. This involves identifying those key scientific breakthroughs that can give birth to new medicines with the potential to benefit those in need. Universities, governments and private industry work together as part of this endeavour. AbbVie strongly supports doctors at research institutions in Cork, Dublin and Galway who are striving to translate scientific breakthroughs into new medicines. We invest in these projects in partnership with Science Foundation Ireland, the Government’s national foundation for investment in scientific research.

AbbVie invested $5.1 billion in research and development (R&D) in 2018 to discover and test compounds with the potential to treat more than 1.5 billion people across the globe. We employ thousands of world-class research scientists who are advancing new science in areas that will be fundamental to tomorrow’s medicines. These scientists build on the latest discoveries in genetics and genomics to develop medicines that are more precisely targeted to the disease and the patient.

We also work with hundreds of partners around the world each year to bring new medicines to patients. For example, we are partnering with Genomics Medicine Ireland and WuXiNextCODE on a 15-year project to sequence the genomes of 45,000 volunteers across Ireland to seek novel insights into the biological processes that underlie complex diseases in areas such as oncology, neuroscience and immunology.

In 2015, we announced a joint €10 million investment with the Department of Jobs, Enterprise and Innovation in two new therapeutic research partnerships.

Phase two: Pipeline and Clinical Trials

A second critical component of our business that benefits society involves clinical trials. This is where we conduct testing in human subjects to evaluate the safety and efficacy of the potential medicines that our discovery process identifies.

Due to its small size, Ireland can be an expensive place to undertake trials and the national commitment to overcoming this challenge is to be admired. AbbVie works closely with doctors at Irish hospitals to do what we can to help ensure they can participate in these potentially vital research trials. We are supported in this by the Health Research Board, a government-funded body that recognises the benefits enrolling patients into clinical trials delivers for the health outcomes of Irish citizens and for the wider economy.

We have built a robust pipeline filled with novel compounds that will provide a consistent stream of innovative medicines to patients and fuel industry-leading performance over the long term. We are researching investigational medicines in 200+ clinical trials in 20+ types of cancer around the world.

Phase three: Operations (Manufacturing)

Of course, our new medicines are only as effective as our ability to make them a reality for patients. This task is handled by AbbVie Operations (manufacturing, quality assurance and distribution).

Operations examine new ways to ensure our discoveries can be manufactured safely to the highest quality standards and distributed to patients around the world. Investing in ground-breaking technologies and platforms allows us to deliver better solutions for patients.

AbbVie manufactures its medicines at 14 locations around the world but three of these plants are based in Ireland. Employing more than 700 highly-skilled workers, our uniquely-focused sites in Cork and Sligo support the manufacture and delivery of portions of our company’s top 20 global products.

Phase four: The Adoption of Innovative Medicines

The adoption of innovative medicines is the fourth and final pillar on which AbbVie’s business rests. Innovative medicines provide compelling patient benefits, differentiated clinical performance and economic value.

• Over the past decade, Ireland has achieved significant improvement in average life expectancy, which increased by almost three years between 2003 and 20121.

• A study of 30 countries undertaken by the Organisation for Economic Cooperation and Development (OECD) between 2000 and 2009 identified an improvement in population weighted mean life expectancy at birth of 1.74 years2.

• Innovative medicines were estimated to have contributed to 73% of this benefit3.

AbbVie’s ability to sustain its discovery, clinical trial and manufacturing commitments is directly linked to the adoption of our innovative medicines.

The adoption of innovative medicines provides the fuel that powers a pharmaceutical firm’s value engine with recognised benefits for Ireland, both at a societal and an individual patient level.

Jeff RedmondAbbVie Ballytivnan, Sligo

Vanessa De AraujoAbbVie Manorhamilton Road, Sligo

Liam CotterAbbVie Cork

A Passion for our People

AbbVie has a high-performing culture that attracts, supports, rewards and develops the dedicated people who come to work with us. Everything we do begins with our passion to positively impact the lives of patients.

We welcome every employee who shares that passion, regardless of race or ethnicity, gender, sexual orientation, gender identity or disability. We strive to ensure a diverse, open and innovative culture for our employees, including our working parents, with opportunities for career advancement and tailored flexibility to enhance the work/life balance.

20 Harnessing heritage and passion to power innovation: The story of AbbVie in Ireland A Passion for our People 2120 Harnessing heritage and passion to power innovation: The story of AbbVie in Ireland

AbbVie launched Women Leaders in Action in 2013, not long after the company’s formation, to help foster a diverse and inclusive environment where every voice is valued and heard.

The group is heavily involved in supporting science education and aims to support and

develop female employees, as well as future generations, in the areas of leadership and STEM to ensure we consistently nurture our pipeline of talent.

The group has almost 2,000 members globally and more than 200 in Ireland, with numbers growing all the time.

Our company has a strong tradition of developing the next generation of Irish employees through dynamic and well-constructed graduate programmes.

The company was a Silver winner of the gradireland Best Internship Programme of the Year 2019, and winner of the Best Graduate Employee of the Year 2017.

AbbVie in Ireland is also incentivising career progression within the organisation using novel initiatives such as our Intern of the Year Award and the Operations Development Programme (ODP), a two-

At AbbVie, we are committed to developing our people both in their professional and personal lives. We create opportunities for innovation, collaboration and demonstrating excellence every day. We offer numerous career paths to help our employees succeed in our different businesses and functions.

The defining feature of a great workplace is the level of trust that exists within it. For employees, a great workplace is one where you trust the people you work with, have great pride in your work, and enjoy what you and your colleagues do.

Women Leaders in Action

Graduate Development

A Great Place to Work

The Great Place to Work (GPTW) Institute assesses the policies and practices in place in organisations worldwide and benchmarks these against other organisations in each country. The Institute conducts an anonymous Trust Index Survey to gather employees’ views and then carries out an in-depth qualitative analysis of open ended comments from employees.

AbbVie was proud to be named Ireland’s number two large workplace at the annual Great Place to Work Awards for 2019. The judging panel commended AbbVie’s ongoing efforts to build a unique culture, the company’s wellness programme, employee development projects, and ongoing commitment to communities and patients.

The Great Place to Work Institute also recognised AbbVie as a Best Workplace for Women at the 2019 awards event. This is the first time the Institute has awarded the accreditation to businesses in Ireland and AbbVie is one of only 13 companies to receive the prestigious honour.

year global career support initiative which focuses on identifying high-potential talent and providing them with a broad base of skills early in their AbbVie careers.

In 2017, AbbVie launched the Technical Development Programme (TDP), a specialist outreach designed to help identify and develop subject matter experts.

AbbVie’s efforts in this area earned the company an Early Career Award trophy for learning and development in 2019.

Members of AbbVie’s Vitality team are pictured with the Ibec KeepWell Mark. The award recognises the company’s commitment to workplace health and well-being. AbbVie is one of first pharmaceutical companies to receive the workplace well-being accolade

22 Harnessing heritage and passion to power innovation: The story of AbbVie in Ireland A Passion for our People 23

Corporate Responsibility

AbbVie takes a comprehensive approach to corporate responsibility focused on three core commitments: improving health outcomes, operating responsibly, and contributing to communities.

We recognise and embrace our responsibility to contribute resources to the improvement of global health. We bring together cutting-edge science, the passion of our employees and the strength of our industry partnerships to find innovative and sustainable solutions to improve the lives of people and communities around the world. We believe in the inherent dignity of every human being.

Our environmental, social and governance efforts have placed us first in the biotechnology industry on the Dow Jones Sustainability Index and made us a constituent of the FTSE 4Good Index.

24 Harnessing heritage and passion to power innovation: The story of AbbVie in Ireland Corporate Responsibility 25

We are committed to the cultivation of a responsible, transparent and inclusive culture to drive sustainable growth. Climate change is one of the most critical issues facing our planet and it has become increasingly important for companies like AbbVie to ensure we help safeguard our planet’s vital resources. We are committed to prioritising sustainability by reducing our direct impacts from manufacturing and by making a positive difference in managing indirect impacts across our value chain.

As part of this ambition we intend to reduce carbon emissions by 25%, achieve a renewable energy consumption target of 50%, and reduce water consumption and waste by 20% each by 2025. Since its foundation in 2013, AbbVie has invested more than €8 million in sustainable and renewable energy programmes in Ireland. All of our Irish manufacturing sites have achieved ISO 50001 certification.

Globally, we reduced absolute total carbon emissions by 13% and increased electricity purchased from renewable sources by 20% between 2015 and 2018.

We believe that our impact as a good corporate citizen begins with the treatment of serious health conditions, but our commitment certainly does not end there. In addition to providing Irish patients with important medicines, we also collaborate with a range of external partners to support patients in many ways, including championing the co-development of unique and sustainable societal healthcare solutions.

AbbVie is committed to offering value beyond the medicine through a number of different initiatives. We enhance patient access to healthcare via patient support services such as AbbVie Care, which helps get the best possible value from their medicines.

Operating Responsibly

Improving Health Outcomes

As global concern rises in relation to water scarcity, it has become increasingly important for AbbVie to help safeguard this vital resource. We reduced our absolute water consumption by 11% in 2018.

Our sites in Ireland have received a number of awards for their efforts in this area including the 2014 Chambers Ireland Excellence in Environment Award; the 2015 Sustainable Energy Achievement Award at the Green Awards; the 2015 SEAI Large Industry Energy Management Award; the 2017 Responsible Care Award at the Pharma Industry Awards; the 2018 Green Pharmaceutical Award at the 2018 Green Awards; the American Chamber of Commerce ‘Créafóg’ Award; and the 2019 Sustainable Energy Achievement award at the 2019 Green Awards.

€8m+invested in Irish sustainable and renewable energy programmes

8%reduction in water consumption

20%increase in electricity purchased from renewable sources

13%global reduction in absolute total carbon emissions

2.3mpatient impacts through 292 AbbVie patient support programmes globally

32conditions treated across infant, adolescent, adult and senior stages of life

Patient organisations are also important partners for AbbVie. The relationships built with patient groups has led to newer and better therapies, and more importantly, enhanced care for patients. Patients are at the centre of everything we do. We constantly strive to understand our patients’ needs and create solutions that will make a difference to patients, their families, their carers and society as a whole.

In order for patients to receive the best care and treatment options, we support our healthcare professionals to stay abreast of developments about new medicines. We also assist them with medical education opportunities, and attendance at congresses and conferences, which help them stay up to date with the latest developments.

Members of AbbVie’s Team Evergreen inspect a recently installed ‘Solar Array’ at the company’s Ballytivnan manufacturing facility in Sligo.


Contributing to Communities

Sustainable returns from the marketplace allow us to ensure we operate in the most environmentally sustainable manner, maintaining industry- leading supply chains and strongly supporting the communities in which we are based, and the people who work for us.

Engagement with those communities is core to our culture…

Our global scale and large workforce mean we make a significant economic contribution to communities everywhere we operate. Engagement with those communities is core to our culture and our employees volunteer tens of thousands of hours each year to assist with community projects.

Our employees demonstrate their commitment to giving back through our company volunteering programmes. Each year, more than 9,000 employees volunteer over 40,000 hours in more than 50 countries, including Ireland, through our signature Week of Possibilities programme.

In Ireland in 2019, more than 250 AbbVie employees volunteered over 1,200 hours across a single week to make a remarkable impact in three Irish communities. Employees from AbbVie’s five sites in Cork, Dublin and Sligo focused their volunteering on projects that would support the company’s ongoing commitment to help transform science education:

Dublin

More than 60 employees from AbbVie’s commercial offices in Citywest, and their manufacturing and engineering services centre in Santry, helped complete an extensive refurbishment of a science laboratory in New Cross College, a DEIS school in Finglas, north Dublin.

Sligo

In Sligo, AbbVie employees from the company’s medical devices centre of excellence in Ballytivnan and from its pharmaceutical plant on the Manorhamilton Road contributed a remarkable 650+ hours to refurbish Ballinode College, a secondary school close to both sites.

Their volunteer efforts included a complete redecoration of the interior and exterior of the school building and a face-lift of the school’s science lab and specialist education rooms.

Cork

In Cork, employees from AbbVie’s manufacturing plant in Carrigtwohill focused their energies on the rejuvenation of science facilities at St Mary’s High School, Midelton. More than 60 AbbVie Cork volunteers helped to revamp the science lab, and carried out other significant interior and exterior redecoration.

As with the efforts in Dublin and Sligo, it is hoped that the volunteer work at St Mary’s High School will help improve the delivery of science-focused education and encourage more students to chose a STEM-related subject and career path.

The Week of Possibilities project was also judged to the best CSR programme by any pharmaceutical company in Ireland at the 2016 Pharma Industry Awards.

9,000+hours volunteered in Ireland since 2014

250+employees volunteered during Week of Possibilities in 2019


Measuring Impact

AbbVie captures the contribution it makes to local communities in an annual Irish corporate responsibility Business Impact Map.

This resource gathers data from 60 of Ireland’s largest companies, including AbbVie, who are members of Business in the Community Ireland and offers a breakdown of how employees support local community groups and charities.

AbbVie Cycle Challenge

During the summer of 2019, dozens of cyclists from across AbbVie’s sites in Ireland, including employees from the US, took to the road for the annual AbbVie Cycle Challenge.

Their goal was to raise much-needed funds for the North West Hospice and Marymount Hospice. To date, more than 250 AbbVie cyclists have pedalled approximately 2,250 km for worthy charities, raising more than €150,000.

AbbVie’s Unique Sporting Partnership

AbbVie agreed a multi-year sponsorship deal with the Sligo GAA county board at the end of 2015. This saw the AbbVie logo appear on all Senior, Under 21 and Junior Gaelic football team jerseys.

Sport plays a very important role in the lives of our employees in Sligo, and our other AbbVie locations in Cork and Dublin. Many of the company’s 400+ Sligo employees are currently involved in the GAA or have previously played the sport at various levels.

This partnership – the only one in Ireland between a multinational pharmaceutical company and an inter-county GAA team – forms part of AbbVie’s ongoing commitment supporting the health and wellbeing of local communities.

AbbVie contributed

€115,000+to worthy Irish projects in 2017

1,700+AbbVie employee volunteer hours in 2018

Niall MurphyCaptain, Sligo Senior Football Team


Science Education

AbbVie aspires to help transform science education in Ireland. This country is a global hub for pharmaceutical, and digital information technology but this internationally significant lead role can only be maintained if young students continue to enter our business sector.

Launched in 2014, and piloted in Ireland, SEEK (Science Engineering Exploration Knowledge) is a global education programme delivered by company volunteers which

aims to spark a child’s interest in science. In 2016, AbbVie launched SEEK Engineering and since its introduction more than 500 Irish schoolchildren have participated in the initiative.

AbbVie also partners with Young Social Innovators (YSI) to run social innovation exchanges which encourage students to consider STEM disciplines as Leaving Cert, third-level, and career options.

Since 2014, more than 150 AbbVie volunteers have assisted in the delivery of more than 60 social innovation workshops and Exchange Days to almost 1,500 students in more than 35 schools in Sligo, Dublin and Cork.

AbbVie is involved in the Science Foundation Ireland Smart Futures programme, Engineers Ireland’s STEPS programme, and the annual Science Week initiative.

Back to School for STEM

AbbVie’s most recent initiative in this area is Back to School for STEM, a schools outreach focused on promoting science role models from the Irish workplace. The initiative encourages greater student awareness of the rewarding career opportunities that can be unlocked by studying STEM subjects.

In 2017, AbbVie published a multi-stakeholder report on the barriers to engagement in science-related subjects and careers. The document highlighted the negative impact low levels of STEM student interest may have on Ireland’s employee

talent pipeline, particularly in high-value pharma, biopharma and medical device sectors.

Among the key recommendations of the STEM Paths report was a need to highlight the positive personal experiences of young people currently working across Irish industry within the STEM disciplines.

The Back to School for STEM initiative will see employees from AbbVie’s five Irish sites visit

schools, including those they themselves studied at, to talk about their jobs and the difference their work makes to wider society.

The initiative, supported by Science Foundation Ireland, was launched at a special event attended by astronaut in training, Dr Norah Patten.

Dr Norah Patten pictured with Columba McGarvey, Site Director,

AbbVie Ballytivnan, Sligo

A budding young scientist pictured at AbbVie’s ‘When I Grow Up’ STEM-focused experience event, which took place during the annual Sligo Science Festival.


1. www.cardi.ie/news/measuringirelandsprogresslifeexpectancygains.2. Lichtenberg, F: Pharmaceutical innovation and longevity

growth in 30 developing OECD and high income countries, 2000-2009. www.nber.org/papers/w18235.

3. IBID.

IE-ABBV-190261 | January 2020


Date post:	15-Aug-2020
Category:	Documents
Upload:	others
View:	0 times
Download:	0 times

Harnessing heritage and passion to power innovation · world-class biopharmaceutical business. We...

Documents